For Patients & Caregivers
At Summit Therapeutics, the unmet healthcare needs of patients is what motivates us to bring the medical solutions needed to make a difference to people’s lives. This page will provide extra information to help you on your healthcare journey.
Clinical Trials
Clinical trials are research studies in which people volunteer to participate. They are designed to answer specific questions about the safety or effectiveness of drugs, other therapies, or new ways of using existing treatments. Thousands of volunteers all around the world participate in clinical trials every year; they decide to do it for many different reasons. The efforts of many people, and especially those that volunteer to participate in clinical trials, help make medical advances happen.
If you or someone you love is on osimertinib for advanced lung cancer:
There is a phase 3 clinical trial, HARMONi, for patients with lung cancer who have an EGFR mutation and have progressed on osimertinib.
Click to Learn More
If you or someone you love has been diagnosed with metastatic non-small cell lung cancer (NSCLC):
There is a phase 3 clinical trial, HARMONi-3, you may want to ask your doctor about.
Click to Learn More
Have you or someone you love been diagnosed with stage 4 PD-L1 high non-small cell lung cancer (NSCLC) that has never been treated?
There is a phase 3 clinical trial called HARMONi-7 that you may want to ask your doctor about.
Click to Learn More
Resource materials
Summit is committed to improving patients’ quality of life, extending their potential lifespan, and addressing serious unmet medical needs. Our goal is to provide access to our medicines at the appropriate time and in the manner that is most beneficial to the relevant patient populations. We believe that participation in our ongoing clinical trials is the safest and most effective way to achieve this goal, and we encourage patients to discuss these options with their physicians.
Currently, our investigational medicine, ivonescimab, is being studied to demonstrate its efficacy and establish its safety profile in patients across North America, Europe as well as Japan. Until ivonescimab’s efficacy and safety are demonstrated, Summit will not be making it available through expanded access. We strongly encourage participation in a clinical trial as the best way to access our investigational therapies. More information about our ongoing clinical trials can be found on the ClinicalTrials.gov website.
In accordance with the 21st Century Cures Act, Summit reserves the right to revise this policy at any time.
For additional information please contact medinfo@smmttx.com.
For additional information please visit the following patient advocacy groups:
